

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-15. (Canceled).

16. (Currently amended) A sustained release preparation comprising a combination of first microcapsules which gradually release a GnRH agonist or a salt thereof for 5 months or longer, and second microcapsules which gradually release a GnRH agonist or a salt thereof for shorter than 5 months so that blood concentration of the GnRH agonist within one week after administration is about 2 ng/mL or higher, wherein:

(a) the first microcapsules comprise:

(i) a GnRH agonist or a salt thereof, and


(ii) a lactic acid polymer having a weight-average molecular weight of about 18,000 to about 30,000; and

(b) the second microcapsules comprise:

(i) a GnRH agonist or a salt thereof, and

(ii) a lactic acid-glycolic acid polymer (75/25 (mol %)) having a weight-average molecular weight of 3,000 to about 12,000, or a lactic acid polymer having a weight-average molecular weight of about 13,000 to about 18,000.

17. (Previously presented) The preparation according to claim 16, wherein the GnRH agonist or a salt thereof is a peptide represented by the formula of SEQ ID NO: 1:



wherein Y represents a residue selected from DLeu, DAla, DTrp, DSer (tBu), D2Nal and DHis (ImBzl), and Z represents NH-C₂H₅ or Gly-NH₂

or a salt thereof.

18. (Previously presented) The preparation according to claim 16, wherein the GnRH agonist or a salt thereof is an acetate of a peptide of the formula of SEQ ID NO: 2:



19. (Canceled)
20. (Previously presented) The preparation according to claim 16, wherein the long term is 5 months or longer and 8 months or shorter, and the short term is 1 week or longer and shorter than 5 months.
21. (Canceled)
22. (Previously presented) The preparation according to claim 16, wherein the ratio of first microcapsules to second microcapsules is from 5:1 to 20:1 expressed as weight ratios of the GnRH agonist or a salt thereof.
23. (Canceled)
24. (Canceled)
25. (Previously presented) The sustained-release preparation according to claim 16, which gradually releases a substantially constant amount of a GnRH agonist or a salt thereof for 5 months or longer.
26. (Canceled)
27. (Previously presented) A composition comprising:
 - (a) a pharmaceutically effective amount for preventing or treating prostate cancer, prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, dysmenorrhea or breast cancer, or for contraception of the sustained-release preparation according to claim 16, and
 - (b) a pharmaceutically acceptable excipient.
28. (Previously presented) A process for producing the sustained-release preparation according to claim 16, which comprises mixing the first and second microcapsules.
29. (Previously presented) A method comprising administering an effective amount for preventing or treating prostate cancer, prostatomegaly, endometriosis, hysteromyoma,

metrofibroma, precocious puberty, dysmenorrhea or breast cancer, or preventing conception of the sustained-release preparation according to claim 16 to a mammal in need thereof.

30. (Previously presented) The preparation according to claim 16, wherein:

(a) the first microcapsules comprise:

(i) a GnRH agonist or a salt thereof, and

(ii) a lactic acid polymer having a weight-average molecular weight of about 21400; and

(b) the second microcapsules:

(1) comprise (i) a GnRH agonist or a salt thereof, and (ii) a lactic acid-glycolic acid polymer (75/25 (mol%)) having a weight-average molecular weight of about 10400, or

(2) comprise (i) a GnRH agonist or a salt thereof, and (ii) a lactic acid polymer having a weight-average molecular weight of about 14200.